Evidence map›Paper›PMID 39753562›Full record

ArticleNPJ Parkinson's disease2025

Neurophysiological gradient in the Parkinsonian subthalamic nucleus as a marker for motor symptoms and apathy.

Elena Bernasconi, Deborah Amstutz, Alberto Averna, Petra Fischer, Mario Sousa, Ines Debove, Katrin Petermann, Laura Alva, Andreia D Magalhães, M Lenard Lachenmayer and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Finely Tuned γ Tracks Medication Cycles in Parkinson's Disease: An Ambulatory Brain-Sense Study.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elena BernasconiDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Deborah AmstutzDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Alberto AvernaDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Petra FischerSchool of Physiology, Pharmacology & Neuroscience, University of Bristol, University Walk, BS8 1TD, Bristol, UK.ORCID http://orcid.org/0000-0001-5585-8977
Mario SousaDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0002-2570-6435
Ines DeboveDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Katrin PetermannDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Laura AlvaDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0002-3585-9961
Andreia D MagalhãesDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
M Lenard LachenmayerDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0003-2952-6383
Thuy-Anh K NguyenDepartment of Neurosurgery, Bern University Hospital and University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0003-0577-5035
Michael SchuepbachInstitute of Neurology, Konolfingen, Switzerland.ORCID http://orcid.org/0000-0003-1382-3359
Andreas NowackiDepartment of Neurosurgery, Bern University Hospital and University of Bern, Bern, Switzerland.
Claudio PolloDepartment of Neurosurgery, Bern University Hospital and University of Bern, Bern, Switzerland.
Paul KrackDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland.
Gerd TinkhauserDepartment of Neurology, Bern University Hospital and University of Bern, Bern, Switzerland. gerd.tinkhauser@insel.ch.ORCID http://orcid.org/0000-0002-1954-1873

Funding

RCUK | Medical Research Council (MRC) MR/Y014863/1Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 186142Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) PZ00P3_202166Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) SNSF 32003B_205156
6 · The paper itself

Abstract

Sensing-based deep brain stimulation should optimally consider both the motor and neuropsychiatric domain to maximize quality of life of Parkinson's disease (PD) patients. Here we characterize the neurophysiological properties of the subthalamic nucleus (STN) in 69 PD patients using a newly established neurophysiological gradient metric and contextualize it with motor symptoms and apathy. We could evidence a STN power gradient that holds most of the spectral information between 5 and 30 Hz spanning along the dorsal-ventral axis. It shows elevated power in the sub-beta range (8-12 Hz) toward the ventral STN, and elevated dorsal beta power (16-24 Hz) indicative for the hemispheres contralateral to the more affected hemi-body side. The rigidity response to DBS was highest dorsally on the axis. Importantly, apathetic symptoms can be related to reduced ventral alpha power. In conclusion, the STN spectral gradient may inform about the motor and neuropsychiatric domain, supporting integrative closed-loop strategies.

Identifiers

PMID39753562
PMCPMC11698975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.